KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Inventory (2020 - 2025)

Moderna (MRNA) has disclosed Inventory for 6 consecutive years, with $153.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Inventory rose 30.77% to $153.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $153.0 million, a 30.77% increase, with the full-year FY2025 number at $153.0 million, up 30.77% from a year prior.
  • Inventory was $153.0 million for Q4 2025 at Moderna, down from $332.0 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $2.1 billion in Q3 2022 to a low of $117.0 million in Q4 2024.
  • A 5-year average of $732.2 million and a median of $490.5 million in 2021 define the central range for Inventory.
  • Peak YoY movement for Inventory: surged 2965.96% in 2021, then tumbled 78.71% in 2023.
  • Moderna's Inventory stood at $1.4 billion in 2021, then plummeted by 34.14% to $949.0 million in 2022, then plummeted by 78.71% to $202.0 million in 2023, then tumbled by 42.08% to $117.0 million in 2024, then soared by 30.77% to $153.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRNA's Inventory are $153.0 million (Q4 2025), $332.0 million (Q3 2025), and $240.0 million (Q2 2025).